within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B05X_IVSolutionAdditives.B05XA30_CombinationsOfElectrolyt;

model CombinationsOfElectrolyt
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 3.333333333333333e-07,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.014,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>CombinationsOfElectrolytes</td></tr><tr><td>ATC code:</td><td>B05XA30</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>14</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.2</td><td>liter/hour</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Combinations of electrolytes encompasses solutions containing multiple essential electrolytes such as sodium, potassium, chloride, calcium, and magnesium. These are typically used for parenteral replenishment of fluid and electrolytes in cases of dehydration, electrolyte imbalances, or during surgery, trauma, or prolonged illness. They are widely approved and used today in hospital and clinical settings.</p><h4>Pharmacokinetics</h4><p>No specific population pharmacokinetic parameters for combinations of electrolytes under ATC B05XA30 are reported in the primary literature. As these mixtures contain physiological ions administered intravenously, pharmacokinetic modeling is generally not conducted in the same way as for other drugs; classical parameters like volume of distribution and clearance are largely determined by patient physiology rather than the formulation.</p><h4>References</h4><ol><li><p>Bateman, RM, et al., &amp; Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. <i>Critical care (London, England)</i> 20(Suppl 2) 94–None. DOI:<a href=\"https://doi.org/10.1186/s13054-016-1208-6\">10.1186/s13054-016-1208-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27885969/\">https://pubmed.ncbi.nlm.nih.gov/27885969</a></p></li><li><p>Yang, S, et al., &amp; Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). <i>Clinical pharmacokinetics</i> 60(7) 887–896. DOI:<a href=\"https://doi.org/10.1007/s40262-021-00988-1\">10.1007/s40262-021-00988-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33598874/\">https://pubmed.ncbi.nlm.nih.gov/33598874</a></p></li><li><p>Levitskaia, TG, et al., &amp; Thrall, KD (2010). Biomaterials for the decorporation of (85)Sr in the rat. <i>Health physics</i> 99(3) 394–400. DOI:<a href=\"https://doi.org/10.1097/HP.0b013e3181c4717d\">10.1097/HP.0b013e3181c4717d</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20699703/\">https://pubmed.ncbi.nlm.nih.gov/20699703</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B05XA30 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end CombinationsOfElectrolyt;
